

Dupixent (dupilumab) Injection Clinical Update

Clinical update: FDA Approves New Dupixent (dupilumab) Pre-Filled Pen Designed to Support More Convenient Self-Administration

FDA approval date: June 18, 2020

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins, and is not an immunosuppressant.

Dupixent is approved in the U.S for the following treatment:

- Patients aged 6 years and older with moderate-to-severe atopic dermatitis, having no effects with prescription therapies used on the skin (topical).
- As a maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in patients aged 12 years and older along with other asthma medicines.
- As a maintenance treatment of CRSwNP in adults along with other medicines.

The Dupixent pre-filled pen was developed based on patient input and offers the latest technology, including visual and audio cues, to help provide support when taking this medicine. The pre-filled pen features a hidden needle and single-press auto-injection, along with visual and audio feedback to help with administration. The 300 mg pre-filled pen is expected to be available in the U.S. in the third quarter of 2020 although pre-filled syringe continues to be available in both 200 mg and 300 mg doses for use in a clinic or at home by self-administration. Both methods of administration require training by a healthcare professional.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.